Abstract
Interleukin-1β (IL-1) and tumor necrosis factor-α (TNF) are important pro-inflammatory cytokines involved in the mediation of the immune response, inflammation, tissue repair, and tumor progression. Regulation of IL-1 and TNF expression is mediated at the level of transcription by the transcription factor NFκB. Inhibition of NFκB activity by the proteasome inhibitor bortezomib (BZ) has been used as a frontline therapy in multiple myeloma and other hematological malignancies. In this chapter, we describe a protocol that uses chromatin immunoprecipitation (ChIP) to analyze the NFκB recruitment to endogenous IL-1 and TNF promoters in BZ-treated human macrophages. Corresponding to the BZ-suppressed mRNA levels of IL-1 and TNF, we show that BZ inhibits p65 NFκB recruitment to IL-1 and TNF promoters. This study specifically uses U937 macrophages, but the protocol could be easily modified to analyze the regulation of NFκB recruitment in other cell types.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732
Lopez-Castejon G, Brough D (2011) Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 22:189–195
Kasza A (2013) IL-1 and EGF regulate expression of genes important in inflammation and cancer. Cytokine 62:22–23
Marusic J, Podlipnik C, Jevsevar S et al (2012) Recognition of human tumor necrosis factor α (TNF-α) by therapeutic antibody fragment: energetics and structural features. J Biol Chem 287:8613–8620
Barbara JA, Van Ostade X, Lopez A (1996) Tumor necrosis factor α (TNF-α): the good, the bad, and potentially very effective. Immunol Cell Biol 74:434–443
Vilcek J, Lee TH (1991) Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem 266:7313–7316
Guoqing C, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634–1635
Mancino A, Lawrence T (2010) NFκB and tumor-associated macrophages. Clin Cancer Res 16:784–789
Baeuerle PA, Baltimore D (1996) NFκB: ten years after. Cell 87:13–20
Baldwin AS (2001) The transcription factor NFκB and human disease. J Clin Invest 107:3–6
Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NFκB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142
Ghosh S, Karin M (2002) Missing pieces in the NFκB puzzle. Cell 109:S81–S96
Wan F, Lenardo MJ (2010) The nuclear signaling of NFκB: current knowledge, new insights, and future perspectives. Cell Res 20:24–33
Prasad S, Ravindran J, Aggarwal BB (2010) NFκB and cancer: how intimate is the relationship. Mol Cell Biochem 336:25–37
Li Q, Withoff S, Verma IM (2005) Inflammation-associated cancer: NFκB is the lynchpin. Trends Immunol 26:318–325
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899
Ghosh S, Hayden MS (2008) New regulators of NFκB in inflammation. Nat Rev Immunol 8:837–848
Hayden MS, Ghosh S (2012) NFκB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26:203–234
Fan Y, Dutta J, Gupta N et al (2008) Regulation of programmed cell death by NFκB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223–250
Hideshima T, Chauhan D, Richardson P et al (2002) NFκB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639–16647
Richardson PG, Mitsiades C, Hideshima T et al (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4:290–296
McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11:164–169
Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:1964–1979
Vu HY, Juvekar A, Ghosh C et al (2008) Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of ΙκΒα. Arch Biochem Biophys 475:156–163
Ghosh CC, Ramaswami S, Juvekar A et al (2010) Gene specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα. J Immunol 185:3685–3693
Juvekar A, Manna S, Ramaswami S et al (2011) Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NFκB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 9:183–194
Manna S, Singha B, Phyo SA et al (2013) Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. J Immunol 191:2837–2846
Singha B, Gatla H, Manna S et al (2014) Proteasome inhibition increases recruitment of IKKβ, S536P-p65 and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 289:2687–2700
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Sanacora, S., Chang, TP., Vancurova, I. (2014). Chromatin Immunoprecipitation Analysis of Bortezomib-Mediated Inhibition of NFκB Recruitment to IL-1β and TNFα Gene Promoters in Human Macrophages. In: Vancurova, I. (eds) Cytokine Bioassays. Methods in Molecular Biology, vol 1172. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0928-5_29
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0928-5_29
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0927-8
Online ISBN: 978-1-4939-0928-5
eBook Packages: Springer Protocols